China
Africa
Explore chapters and articles related to this topic
Endocrine Disorders, Contraception, and Hormone Therapy during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
There has been one case report of an ear malformation in an infant exposed to the oral hypoglycemic agent tolazamide during the first 12 weeks of gestation (Piacquadio et al., 1991). It should be avoided in pregnancy since both tolazamide and tolbutamide will not provide good control in pregnant patients who cannot be controlled by diet alone (Friend, 1981).
Drugs Affecting the Endocrine System
Published in Radhwan Nidal Al-Zidan, Drugs in Pregnancy, 2020
Risk Summary: It should be used with caution during the 1st and 2nd Trimesters. However, it is better to avoid the use of Tolazamide during the 3rd Trimester because fetal toxicity has been associated with its use during the last Trimester.
Predicting successful/unsuccessful extrapolation for in vivo total clearance of model compounds with a variety of hepatic intrinsic metabolism and protein bindings in humans from pharmacokinetic data using chimeric mice with humanised liver
Published in Xenobiotica, 2020
Takeshi Sawada, Yoshiyuki Yamaura, Satonori Higuchi, Haruo Imawaka, Hiroshi Yamazaki
The concentrations of test compounds in plasma from humanised-liver mice were determined by liquid chromatography–tandem mass spectrometry (Triple Quad 6500; AB Sciex, Framingham, MA, USA). Tolazamide was used as an internal standard. SUMIPAX ODS Z-CLUE [2.0 mm internal diameter (I.D.) × 50 mm; particle size, 3.0 μm, Sumika Chemical Analysis Service, Osaka, Japan] was used as the analytical column. Mobile phase A was 0.1% (v/v) formate or 10 mmol/L ammonium acetate, while mobile phase B was methanol. Mobile phase B was maintained at 15% between 0 and 1 min, increased to 90% gradually from 1 to 5 min, and then increased to 95% gradually from 5 to 7.5 min. The composition of mobile phase B was then restored to 15% and allowed to re-equilibrate for 2.5 min. The ionisation mode and the mass number of the molecular ion and product ion are shown in Table 1 (method 1).
A randomized study on the usefulness of an electronic outpatient hypoglycemia risk calculator for clinicians of patients with diabetes in a safety-net institution
Published in Current Medical Research and Opinion, 2020
Michael Weiner, Jonathan Cummins, Annaswamy Raji, Susan Ofner, Kristy Iglay, Evgenia Teal, Xiaochun Li, Samuel S. Engel, Kristina Knapp, Swapnil Rajpathak, Jarod Baker, Arnaub K. Chatterjee, Larry Radican
We randomized primary care clinicians who provide outpatient care at Eskenazi Health, to see, or not see, the alert tool in outpatient clinical practice, for four months. For clinicians in the intervention group, the tool was displayed for all outpatients who were 21 or more years of age and were prescribed any of the following drugs for DM: acarbose, acetohexamide, alogliptin, canagliflozin, chlorpropamide, colesevelam, dapagliflozin, exenatide, glibenclamide, glimepiride, glipizide, glyburide, insulin, linagliptin, liraglutide, meglitol, metformin, nateglinide, pioglitazone, pramlintide, repaglinide, rosiglitazone, saxagliptin, sitagliptin, tolazamide, or voglibose. During the five-month follow-up period, we assessed patients’ characteristics, prescriptions, diagnostic testing, and HG. Clinicians randomized to the control group did not see the computerized alert tool displayed for their patients while logged into the EHR.
Home management of pediatric sulfonylurea ingestions
Published in Clinical Toxicology, 2022
Courtney Temple, Ruby Hoang, Shana Kusin
Our findings suggest that there is a subset of pediatric patients who can safely be monitored at home, and that the risk of potential delayed presentation of these patients, even if they do develop hypoglycemia, is low. Children ≤5 years who have ingested small amounts of second-generation sulfonylureas should be considered candidates for home observation with reliable caregivers able to use glucose monitoring equipment, and close SPI follow up. We continue to recommend HCF referral for cases involving any first-generation sulfonylurea (acetohexamide, chlorpropamide, tolazamide, or tolbutamide), >1 tablet, extended-release formulations, or >4 mg of glimepiride.